Larimar Therapeutics, Inc. LRMR 深 沪
已收盘 08-07 16:00:00 美东时间
4.16
-0.040
-0.95%
华盛通- 最 高4.31
- 今 开4.24
- 成交量 62.78万股
- 最 低 3.82
- 昨 收 4.20
- 总市值 7.37万
- 52周最高 6.42
- 市盈率 静 --
- 换手率 3544.73%
- 52周最低 2.715
- 委 比 72.84%
- 总股本 1.77万
- 历史最高 664.32
- 量 比 0.56
- 振 幅 11.67%
- 历史最低 1.10
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Larimar Therapeutics shares are trading lower. The company reported Q1 EPS results.
Larimar Therapeutics shares are trading lower. The company reported Q1 EPS resu...
05-15 01:36
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Larimar Therapeutics Q4 EPS $(0.73) Misses $(0.45) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.45) by 62.22 percent. This is a 62.22 percent decrease over losses of $(0.45) per share
03-19 19:08
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views
U.S. stocks traded higher midway through trading, with the Dow Jones index gain...
02-25 01:38
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
Larimar Therapeutics announced FDA recommendations for safety database requirements for nomlabofusp's BLA submission seeking accelerated approval for Friedreich’s Ataxia (FA). The company plans to submit the BLA in Q2 2026, following expected OLE and adolescent PK data in September 2025. Global Phase 3 study preparations are ongoing, with sites identified in multiple regions. Nomlabofusp has the potential to be the first disease-modifying therapy for FA.
2025-06-23 11:00
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
Larimar Therapeutics will host a conference call and webcast on June 23, 2025, at 8:00 am EDT to discuss regulatory updates for its nomlabofusp clinical program targeting Friedreich’s Ataxia. Participants can join via phone or the provided link, with an archived webcast available post-event on the company’s website. Larimar is a biotech company developing treatments for rare diseases, with nomlabofusp as its lead compound.
2025-06-20 20:05
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 poin...
2024-09-06 01:44
Baird Initiates Coverage On Larimar Therapeutics with Outperform Rating, Announces Price Target of $16
Baird analyst Joel Beatty initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and announces Price Target of $16.
2024-09-04 17:42
